Lantern (LTRN) - Final Profit

LTRN (Lantern Pharma Inc.) - company brandmark

Lantern Pharma Inc. (LTRN) competes in a crowded targeted therapy segment where the battle for efficacy is fought over marginal percentages. The business relies on stable demand, remaining a defensive asset regardless of macroeconomic conditions. The RADR AI platform accelerates drug development for the B2B sector. The company's financial results demonstrate profit dynamics, where the indicator value reaches -0.02.

Lantern Pharma (LTRN): Net Profit from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for lanternpharma.com (LTRN)

- current quotes and average value forecast:
Market Chart Lantern Pharma|LTRN - Consensus Target
- market capitalization indicators:
Market Value LTRN|LTRN - Enterprise Value
- business book valuation details:
Accounting Value per Share Lantern Pharma|LTRN - Book Capitalization|Market Capitalization to Book Value Ratio lanternpharma.com|LTRN - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Ratio Lantern Pharma Inc.|LTRN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Lantern Pharma|LTRN - Company Aggregate Debts|Debts to Book Value LTRN|LTRN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lantern Pharma|Quick Liquidity lanternpharma.com
- net income and valuation ratios data:
LTRN - Net Profit
Fundamental valuation:LTRN Lantern
Brand item of Lantern Pharma Inc

The efficiency of the RADR AI platform in optimizing oncology drug development costs directly determines the net income dynamics of Lantern Pharma Inc. (LTRN). This chart captures daily margins, allowing investors to instantly identify hidden management costs and assess the real capital cushion, where sharp spikes in profitability may signal a correction risk should the market trend shift.

Main competitors

AVBP - Net Financial Result|Net Income BIAF|EFTR: Final Profit